BioMedTracker is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
All Special Reports
Datamonitor Healthcare Osteoporosis KOL Interviews
Retail Price: $599.00*BioMedTracker Subscriber Price: $399.00 - click here to log in February 03, 2017 Datamonitor Healthcare interviewed an endocrinologist based in the US and a rheumatologist based in the UK to gauge their views on current treatment options, late stage clinical candidates, treatment challenges and unmet needs in osteoporosis. The drugs discussed include abaloparatide (RDUS), Atelvia (AGN), Evenity (AMGN), Evista (LLY), Forteo (LLY), Fosamax (MRK), Prolia (AMGN) and Reclast (NVS). The two interviews were combined into a single report.
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.